SANCTURA XR Drug Patent Profile

Which patents cover Sanctura Xr, and when can generic versions of Sanctura Xr launch?

Sanctura Xr is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sanctura Xr

A generic version of SANCTURA XR was approved as trospium chloride by GLENMARK PHARMS LTD on August 13^th, 2010.

Summary for SANCTURA XR

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SANCTURA XR

Paragraph IV (Patent) Challenges for SANCTURA XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SANCTURA XR	Extended-release Capsules	trospium chloride	60 mg	022103	1	2009-03-02

US Patents and Regulatory Information for SANCTURA XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007		DISCN	Yes	No

International Patents for SANCTURA XR

See the table below for patents covering SANCTURA XR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5610663
European Patent Office	2210605	Forme dosifiée quotidienne de trospium (Once daily dosage forms of trospium)
Spain	2359375

SANCTURA XR: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

SANCTURA XR (trospium chloride extended-release) is a prescription medication indicated for overactive bladder (OAB). As a non-anticholinergic treatment option, SANCTURA XR is positioned to capture a significant segment of the OAB therapeutics market, which is projected to grow substantially over the next decade. This report evaluates SANCTURA XR's current market landscape, potential investment opportunities, competitive dynamics, and financial prospects based on recent clinical, regulatory, and commercial data.

---

What is the Current Market Status of SANCTURA XR?

Product Profile and Regulatory Status

Attribute	Description
Active Ingredient	Trospium chloride (extended-release form)
Approved in	U.S. FDA (approved in 2014), EMA (approved in 2015)
Indication	Overactive bladder (OAB)
Formulation	60 mg extended-release tablets
Patent Status	Patent expired in 2020; generic versions available
Orphan/Exclusive Rights	No exclusive rights post-patent expiration

Market Penetration & Sales Data

• 2014-2022 Revenue Trends: Peak sales in 2015 at approximately $250 million in the U.S.
• Sales Decline Post-Patent: By 2022, sales declined to ~$60 million due to patent expiry and generic competition (IQVIA, 2022).
• Market Penetration: Historically, SANCTURA XR captured ~12% of the U.S. OAB drug market pre-patent expiry.

Key Factors Affecting Sales

Factor	Impact
Patent expiration	Led to generic entry, reducing brand sales
Competition from generics	Intensified price competition and reduced margins
Efficacy and tolerability profile	Moderate, which influences physician switching patterns

---

Market Dynamics: Key Drivers and Challenges

Market Drivers

Driver	Explanation
Rising prevalence of OAB	Approximately 33 million adults affected in the U.S. (NIH, 2021)
Aging population	Elderly (65+) population expected to grow 38% by 2030, increasing OAB cases
Preference for non-invasive therapies	Oral medications like SANCTURA XR preferred over procedures
Advancements in drug formulations	Extended-release formulations improve adherence

Competitive Landscape

Competitor	Market Share	Key Attributes	Price/Cost Position
Ditropan XL (oxybutynin)	~50%	First-line, established, generic available	Low cost, high efficacy
Myrbetriq (mirabegron)	~35%	Beta-3 adrenergic agonist, non-anticholinergic	Premium pricing
Vesicare (solifenacin)	~10%	Selective antimuscarinic, branded	Moderate to high cost
SANCTURA XR (trospium)	Remaining %	Non-anticholinergic, fewer central nervous system side effects	Moderate, facing competition

Regulatory and Market Challenges

• Patent expiration has led to increased availability of generics, pressuring prices.
• Physician preference shifting towards newer agents like mirabegron.
• Side effect profiles influence adherence; SANCTURA XR exhibits low CNS penetration but gastrointestinal effects remain concerns.

---

Financial Trajectory and Investment Outlook

Historical Financials

Year	Revenue (USD million)	Market Share	Notes
2014	250	Peak	Post-approval success, patent protected
2016	150	Decline	Patent expiry, generics entry
2020	80	Reducing	Competition intensifies
2022	60	Low	Market contraction

Projected Revenue Trends (2023-2030)

Year	Estimated Revenue (USD million)	Assumptions
2023	45	Entry of biosimilars, aggressive generic pricing
2025	30	Market stabilization, limited innovative labeling
2027	20	Continued generic dominance, minimal branded sales
2030	15	Market maturity with low incremental growth

Factors Influencing Financial Trajectory

Factor	Effect
Patent expiration	Continuing decline in original product revenue
Market acceptance of generics	Lower prices, compressing margins
Development of new formulations or combos	Potential for revenue uplift if successful
Entry of new therapeutics	Highly competitive landscape reduces incremental gains

Investment Considerations

Criterion	Analysis
Revenue stability	Declining without innovation or pipeline expansion
Market growth	Growing OAB prevalence underpins long-term opportunity
Competitive positioning	Loss of exclusivity diminishes profit margins
R&D pipeline prospects	Critical for future growth and valuation
Regulatory prospects	Opportunities for reformulations or novel indications

---

Comparison with Key Competitors

Aspect	SANCTURA XR	Mirabegron (Myrbetriq)	Oxybutynin (Ditropan XL)
Mechanism	Anticholinergic (antimuscarinic)	Beta-3 adrenergic receptor agonist	Anticholinergic
Patent Status	Expired	Patented (still under patent)	Patent expired
Side Effect Profile	Low CNS penetration, GI effects	Fewer anticholinergic side effects	Anticholinergic adverse effects
Administration	Oral, extended-release	Oral, immediate and extended-release	Oral, immediate or extended-release
Market Share (2022)	Declining	Growing (~35% in OAB market)	Declining (~50% pre-2015)
Pricing	Moderate	Premium	Low (generic)

---

Deep Dive: Regulatory and Policy Impacts

Policy Area	Implication for SANCTURA XR
Patent policy and exclusivity laws	Patent expiry in 2020; generic competition inevitable
Healthcare reimbursement policies	Shift towards cost-effective generics, pressure on branded drugs
Incentives for innovation	Need for pipeline development to sustain ROI
Quality and safety regulations	Compliance necessary for future approvals

---

Future Market Opportunities

• Combination therapies: Potential for SANCTURA XR in fixed-dose combinations to improve adherence.
• Novel indications: Exploration of SANCTURA XR for other neurological or urinary conditions.
• Formulation innovations: Development of longer-acting or less side-effect-prone variants.
• Geographic expansion: Emerging markets (Asia, Latin America) could provide growth avenues, subject to regulatory approval.

---

Key Takeaways

• Post-patent decline has significantly reduced SANCTURA XR revenues, with a projected decline to ~$15 million by 2030.
• Market dynamics favor newer agents like mirabegron, which capture a growing share due to better tolerability and efficacy.
• The overarching challenge for SANCTURA XR lies in maintaining relevance beyond the patent expiry, requiring R&D innovation.
• Investment prospects depend on pipeline strength, pipeline diversification, and ability to adapt to competitive pressures.
• Long-term viability hinges on regenerative strategies such as reformulation, combination therapies, or expanding indications.

---

FAQs

1. Will SANCTURA XR regain market share post-patent expiry?
Unlikely, unless supported by significant innovation, as generic competition dominates price-sensitive markets.

2. Are there ongoing R&D initiatives for SANCTURA XR?
No publicly disclosed pipeline programs specific to SANCTURA XR; future prospects depend on company strategic R&D focus.

3. How does SANCTURA XR compare to newer therapies like mirabegron?
Mirabegron offers favorable side-effect profiles and easier tolerability, gaining market preference over SANCTURA XR.

4. What are the primary barriers to SANCTURA XR's market expansion?
Generic entry, patent expiration, physician preference shifts, and cost considerations.

5. Could biosimilars or new formulations revive SANCTURA XR's market potential?
Potentially, but such developments require substantial investment and regulatory approval; current data do not support imminent breakthroughs.

---

References

1. IQVIA. (2022). U.S. Pharmaceutical Market Data.
2. National Institutes of Health (NIH). (2021). Overactive Bladder Prevalence and Impact.
3. U.S. Food and Drug Administration (FDA). (2014-2022). Drug Approvals and Labeling.
4. European Medicines Agency (EMA). (2015). Sanctura XR Approval Details.
5. Market Research Future. (2022). Global Overactive Bladder Therapeutics Market Analysis.

---

End of Report